Evaluations › SBU · Last reviewed 2026-05-16

SBU (Sweden, 2022)

SBU. Hormone treatment of children and adolescents with gender dysphoria. Report 342 (registration no. SBU 2020/426). Stockholm: Swedish Agency for Health Technology Assessment and Assessment of Social Services; 22 February 2022 (source). Position in chronology: timeline 2022-02.

Summary

The Swedish Agency for Health Technology Assessment (SBU) carried out a systematic review of hormone treatment in adolescents with gender dysphoria. Of 9,934 potential studies whose abstracts were reviewed, 24 were relevant. No randomised controlled trials were found, the few longitudinal observational studies were hampered by small numbers and high attrition, and the review concluded that the evidence is insufficient to assess the effects of hormone treatment on psychosocial and mental health, cognition, body composition and metabolic markers (source).

1. Methodology

  • Systematic review that essentially follows PRISMA; PubMed, EMBASE and thirteen other databases were searched until 9 November 2021 (source).
  • English-language studies of hormone treatment (GnRHa or cross-sex hormones) in children and adolescents with gender dysphoria; outcomes were psychosocial and mental health, cognition, body composition and metabolic markers.

2. Conclusions

  • Evidence is insufficient to assess the effects of hormone treatment on psychosocial and mental health, cognition, body composition and metabolic markers.
  • The long-term effects of hormone therapy on psychosocial health could not be evaluated.
  • GnRHa treatment delays bone maturation and gain in bone mineral density, which partially recovered during cross-sex hormone treatment when studied at age 22.
  • SBU itself issues no recommendations; the Swedish Socialstyrelsen recommends, in view of the SBU conclusion, that these treatments be provided in the context of research (source).

See also